Anti-tumor effects of genetic vaccines against HPV major oncogenes

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 1, 2015, Pages 45-52

  Cordeiro, Marcelo Nazário ^a   Paolini, Francesca ^b   Massa, Silvia ^c   Curzio, Gianfranca ^b   Illiano, Elena ^d   Silva, Anna Jéssica Duarte ^a   Franconi, Rosella ^c   Bissa, Massimiliano ^d   De Giuli Morghen, Carlo ^d   De Freitas, Antonio Carlos ^a   Venuti, Aldo ^b  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c ENEA   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

C3 cell line; DNA vaccines; HPV16 E5; Human papillomavirus; Immunologic response

Indexed keywords

PAPILLOMAVIRUS E5 PROTEIN; PROTEIN E6; PROTEIN E7; PROTEIN P53; UNCLASSIFIED DRUG; VIRUS PROTEIN; DNA VACCINE; ONCOGENE PROTEIN E5, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; WART VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CODON; CONTROLLED STUDY; EMBRYO; FEMALE; GENE EXPRESSION; GENETIC IMMUNIZATION; IMMUNOLOGY; IMMUNOTHERAPY; MOUSE; NONHUMAN; TUMOR CELL; WART VIRUS; ANIMAL; C57BL MOUSE; GENETICS; HUMAN PAPILLOMAVIRUS TYPE 16; TUMOR CELL LINE; UTERINE CERVICAL NEOPLASMS;

ANIMALS; CELL LINE, TUMOR; FEMALE; HUMAN PAPILLOMAVIRUS 16; MICE, INBRED C57BL; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINES, DNA;

EID: 84922495839     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.34303     Document Type: Article

References (45)

1. Guan P, Howell-Jones R, Li N, Bruni L, de Sanjosé S, Franceschi S, Clifford GM. Human papillomavirus types in 115, 789 HPV-positive women: A meta-analysis from cervical infection to cancer. Int J Cancer 2012; 131: 2349-59; PMID: 22323075; http://dx.doi.org/10.1002/ijc.27485
2. Burchell AN, Winer RL, de Sanjosé S, Franco EL. Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine 2006; 24(Suppl 3): S3, 52-61; PMID: 16950018; http://dx.doi.org/10.1016/j.vaccine.2006.05.031
3. zur Hausen H. Papillomaviruses and cancer: From basic studies to clinical application. [Review]. Nat Rev Cancer 2002; 2: 342-50; PMID: 12044010; http://dx.doi.org/10.1038/nrc798
4. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-27; PMID: 12571259; http://dx.doi.org/10.1056/NEJMoa021641
5. Bzhalava D, Guan P, Franceschi S, Dillner J, Clifford G. A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types. Virology 2013; 445: 224-31; PMID: 23928291; http://dx.doi.org/10.1016/j.virol.2013.07.015
6. zur Hausen H. Papillomaviruses in the causation of human cancers -A brief historical account. Virology 2009; 384: 260-5; PMID: 19135222; http://dx.doi.org/10.1016/j.virol.2008.11.046
7. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Symer DE, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000; 92: 709-20; PMID: 10793107; http://dx.doi.org/10.1093/jnci/92.9.709
8. Herrero R, Castellsagué X, Pawlita M, Lissowska J, Kee F, Balaram P, Rajkumar T, Sridhar H, Rose B, Pintos J, et al.; IARC Multicenter Oral Cancer Study Group. Human papillomavirus and oral cancer: The International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 2003; 95: 1772-83; PMID: 14652239; http://dx.doi.org/10.1093/jnci/djg107
9. Struyk L, van der Meijden E, Minnaar R, Fontaine V, Meijer I, ter Schegget J. Transcriptional regulation of human papillomavirus type 16 LCR by different C/EBPbeta isoforms. Mol Carcinog 2000; 28: 42-50; PMID: 10820487; http://dx.doi.org/10.1002/(SICI )1098 -2744 (200005)28 : 1 3.0.CO;2-8
10. Barbaresi S, Cortese MS, Quinn J, Ashrafi GH, Graham SV, Campo MS. Effects of human papillomavirus type 16 E5 deletion mutants on epithelial morphology: Functional characterization of each transmembrane domain. J Gen Virol 2010; 91: 521-30; PMID: 19812262; http://dx.doi.org/10.1099/vir.0.016295-0
11. White EA, Sowa ME, Tan MJ, Jeudy S, Hayes SD, Santha S, Münger K, Harper JW, Howley PM. Systematic identification of interactions between host cell proteins and E7 oncoproteins from diverse human papillomaviruses. Proc Natl Acad Sci U S A 2012; 109: E260-7; PMID: 22232672; http://dx.doi.org/10.1073/pnas.1116776109
12. Fu B, Quintero J, Baker CC. Keratinocyte growth conditions modulate telomerase expression, senescence, and immortalization by human papillomavirus type 16 E6 and E7 oncogenes. Cancer Res 2003; 63: 7815-24; PMID: 14633708
13. Kim M-K, Kim HS, Kim S-H, Oh J-M, Han JY, Lim JM, Juhnn YS, Song YS. Human papillomavirus type 16 E5 oncoprotein as a new target for cervical cancer treatment. Biochem Pharmacol 2010; 80: 1930-5; PMID: 20643111; http://dx.doi.org/10.1016/j.bcp.2010.07.013
14. DiMaio D, Mattoon D. Mechanisms of cell transformation by papillomavirus E5 proteins. Oncogene 2001; 20: 7866-73; PMID: 11753669; http://dx.doi.org/10.1038/sj.onc.1204915
15. Hwang ES, Nottoli T, Dimaio D. The HPV16 E5 protein: Expression, detection, and stable complex formation with transmembrane proteins in COS cells. Virology 1995; 211: 227-33; PMID: 7645215; http://dx.doi.org/10.1006/viro.1995.1395
16. Straight SW, Hinkle PM, Jewers RJ, McCance DJ. The E5 oncoprotein of human papillomavirus type 16 transforms fibroblasts and effects the downregulation of the epidermal growth factor receptor in keratinocytes. J Virol 1993; 67: 4521-32; PMID: 8392596
17. Rodríguez MI, Finbow ME, Alonso A. Binding of human papillomavirus 16 E5 to the 16 kDa subunit c (proteolipid) of the vacuolar H+-ATPase can be dissociated from the E5-mediated epidermal growth factor receptor overactivation. Oncogene 2000; 19: 3727-32; PMID: 10949926; http://dx.doi.org/10.1038/sj.onc.1203718
18. Ashrafi GH, Haghshenas M, Marchetti B, Campo MS. E5 protein of human papillomavirus 16 downregulates HLA class I and interacts with the heavy chain via its first hydrophobic domain. Int J Cancer 2006; 119: 2105-12; PMID: 16823848; http://dx.doi.org/10.1002/ijc.22089
19. Venuti A, Paolini F, Nasir L, Corteggio A, Roperto S, Campo MS, Borzacchiello G. Papillomavirus E5: The smallest oncoprotein with many functions. Mol Cancer 2011; 10: 140; PMID: 22078316; http://dx.doi.org/10.1186/1476-4598-10-140
20. Cheng W-F, Hung C-F, Chai C-Y, Hsu K-F, He L, Ling M, Wu TC. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 2001; 108: 669-78; PMID: 11544272; http://dx.doi.org/10.1172/JCI200112346
21. Peng S, Ji H, Trimble C, He L, Tsai Y-C, Yeatermeyer J, Boyd DA, Hung CF, Wu TC. Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6. J Virol 2004; 78: 8468-76; PMID: 15280455; http://dx.doi.org/10.1128/JVI.78.16.8468-8476.2004
22. Diniz MO, Lasaro MO, Ertl HC, Ferreira LCS. Immune responses and therapeutic antitumor effects of an experimental DNA vaccine encoding human papillomavirus type 16 oncoproteins genetically fused to herpesvirus glycoprotein D. Clin Vaccine Immunol 2010; 17: 1576-83; PMID: 20739505; http://dx.doi.org/10.1128/CVI.00264-10
23. Gill DK, Bible JM, Biswas C, Kell B, Best JM, Punchard NA, Cason J. Proliferative T-cell responses to human papillomavirus type 16 E5 are decreased amongst women with high-grade neoplasia. J Gen Virol 1998; 79: 1971-6; PMID: 9714245
24. Liu DW, Tsao YP, Hsieh CH, Hsieh JT, Kung JT, Chiang CL, Huang SJ, Chen SL. Induction of CD8 T cells by vaccination with recombinant adenovirus expressing human papillomavirus type 16 E5 gene reduces tumor growth. J Virol 2000; 74: 9083-9; PMID: 10982354; http://dx.doi.org/10.1128/JVI.74.19.9083-9089.2000
25. Kanodia S, Da Silva DM, Kast WM. Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int J Cancer 2008; 122: 247-59; PMID: 17973257; http://dx.doi.org/10.1002/ijc.23252
26. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, Drijfhout JW, ter Schegget J, Melief CJ, Kast WM. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993; 23: 2242-9; PMID: 7690326; http://dx.doi.org/10.1002/eji.1830230929
27. Massa S, Simeone P, Muller A, Benvenuto E, Venuti A, Franconi R. Antitumor activity of DNA vaccines based on the human papillomavirus-16 E7 protein genetically fused to a plant virus coat protein. Hum Gene Ther 2008; 19: 354-64; PMID: 18439124; http://dx.doi.org/10.1089/hum.2007.122
28. Massa S, Paolini F, Spanò L, Franconi R, Venuti A. Mutants of plant genes for developing cancer vaccines. Hum Vaccin 2011; 7(Suppl): 147-55; PMID: 21266841; http://dx.doi.org/10.4161/hv.7.0.14577
29. Liu D-W, Yang Y-C, Lin H-F, Lin M-F, Cheng Y-W, Chu C-C, Tsao YP, Chen SL. Cytotoxic T-lymphocyte responses to human papillomavirus type 16 E5 and E7 proteins and HLA-A. 0201-restricted T-cell peptides in cervical cancer patients. J Virol 2007; 81: 2869-79; PMID: 17202211; http://dx.doi.org/10.1128/JVI.02256-06
30. Chen Y-F, Lin C-W, Tsao Y-P, Chen S-L. Cytotoxic-T-lymphocyte human papillomavirus type 16 E5 peptide with CpG-oligodeoxynucleotide can eliminate tumor growth in C57BL/6 mice. J Virol 2004; 78: 1333-43; PMID: 14722288; http://dx.doi.org/10.1128/JVI.78.3.1333-1343.2004
31. Smahel M, Síma P, Ludvíková V, Vonka V. Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells. Virology 2001; 281: 231-8; PMID: 11277695; http://dx.doi.org/10.1006/viro.2000.0794
32. Smahel M, Síma P, Ludvíková V, Marinov I, Pokorná D, Vonka V. Immunisation with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules. Vaccine 2003; 21: 1125-36; PMID: 12559790; http://dx.doi.org/10.1016/S0264-410X(02)00519-4
33. Massa S, Franconi R, Brandi R, Muller A, Mett V, Yusibov V, Venuti A. Anti-cancer activity of plantproduced HPV16 E7 vaccine. Vaccine 2007; 25: 3018-21; PMID: 17280752; http://dx.doi.org/10.1016/j.vaccine.2007.01.018
34. Venuti A, Massa S, Mett V, Vedova LD, Paolini F, Franconi R, Yusibov V. An E7-based therapeutic vaccine protects mice against HPV16 associated cancer. Vaccine 2009; 27: 3395-7; PMID: 19200826; http://dx.doi.org/10.1016/j.vaccine.2009.01.068
35. Disbrow GL, Sunitha I, Baker CC, Hanover J, Schlegel R. Codon optimization of the HPV-16 E5 gene enhances protein expression. Virology 2003; 311: 105-14; PMID: 12832208; http://dx.doi.org/10.1016/S0042-6822(03)00129-6
36. Oetke C, Auvinen E, Pawlita M, Alonso A. Human papillomavirus type 16 E5 protein localizes to the Golgi apparatus but does not grossly affect cellular glycosylation. Arch Virol 2000; 145: 2183-91; PMID: 11087100; http://dx.doi.org/10.1007/s007050070048
37. Wetherill LF, Holmes KK, Verow M, Müller M, Howell G, Harris M, Fishwick C, Stonehouse N, Foster R, Blair GE, et al. High-risk human papillomavirus E5 oncoprotein displays channel-forming activity sensitive to small-molecule inhibitors. J Virol 2012; 86: 5341-51; PMID: 22357280; http://dx.doi.org/10.1128/JVI.06243-11
38. Yang DH, Wildeman AG, Sharom FJ. Overexpression, purification, and structural analysis of the hydrophobic E5 protein from human papillomavirus type 16. Protein Expr Purif 2003; 30: 1-10; PMID: 12821315; http://dx.doi.org/10.1016/S1046-5928(03)00049-4
39. Lee SY, Huang Z, Kang TH, Soong R-S, Knoff J, Axenfeld E, Wang C, Alvarez RD, Chen CS, Hung CF, et al. Histone deacetylase inhibitor AR-42 enhances E7-specific CD8+ T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination. J Mol Med (Berl) 2013; 91: 1221-31; PMID: 23715898; http://dx.doi.org/10.1007/s00109-013-1054-9
40. Lin K, Roosinovich E, Ma B, Hung CF, Wu TC. Therapeutic HPV DNA vaccines. Immunol Res 2010; 47: 86-112; PMID: 20066511; http://dx.doi.org/10.1007/s12026-009-8141-6
41. Vici P, Mariani L, Pizzuti L, Sergi D, Di Lauro L, Vizza E, Tomao F, Tomao S, Cavallotti C, Paolini F, et al. Immunologic treatments for precancerous lesions and uterine cervical cancer. J Exp Clin Cancer Res 2014; 33: 29; PMID: 24667138; http://dx.doi.org/10.1186/1756-9966-33-29
42. Ristriani T, Fournane S, Orfanoudakis G, Travé G, Masson M. A single-codon mutation converts HPV16 E6 oncoprotein into a potential tumor suppressor, which induces p53-dependent senescence of HPV-positive HeLa cervical cancer cells. Oncogene 2009; 28: 762-72; PMID: 19015633; http://dx.doi.org/10.1038/onc.2008.422
43. Ramos CR, Abreu PA, Nascimento AL, Ho PL. A high-copy T7 Escherichia coli expression vector for the production of recombinant proteins with a minimal N-terminal His-tagged fusion peptide. Braz J Med Biol Res 2004; 37: 1103-9; PMID: 15273812; http://dx.doi.org/10.1590/S0100-879X2004000800001
44. Miyahira Y, Murata K, Rodriguez D, Rodriguez JR, Esteban M, Rodrigues MM, Zavala F. Quantification of antigen specific CD8+ T cells using an ELISPOT assay. J Immunol Methods 1995; 181: 45-54; PMID: 7537312; http://dx.doi.org/10.1016/0022-1759(94)00327-S
45. Seo SH, Jin HT, Park SH, Youn JI, Sung YC. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation. Vaccine 2009; 27: 5906-12; PMID: 19651174; http://dx.doi.org/10.1016/j.vaccine.2009.07.033v